Investigational drug · Phase 2
OHB-607
Also called: Mecasermin Rinfabate
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "OHB-607"
First trial start
2019
May 9, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OHB-607", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bronchopulmonary Dysplasia
- Chronic Lung Disease of Prematurity
- Intraventricular Hemorrhage
- Retinopathy of Prematurity (ROP)
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "OHB-607" as an intervention, largest first.
- A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsPivotal-lookingActive, not recruiting
OHB Neonatology Ltd.Industry
NCT03253263 · 295 participants · Start May 9, 2019 · Primary completion Jul 31, 2026
Drug: OHB-607 · For: Bronchopulmonary Dysplasia; Chronic Lung Disease of Prematurity; Intraventricular Hemorrhage and 1 more
Sites: Little Rock, Arkansas; California City, California; Los Angeles, California · 62 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Translational Development of Physiologic IGF-1 Replacement for the Prevention of Bronchopulmonary Dysplasia.
Niklas V, Barton N · Biomedicines 2026
- Insulin-like growth factor-1 for the prevention or treatment of retinopathy of prematurity.
Trzaski JM, Cracknell J, Herbst KW, et al. · Cochrane Database Syst Rev 2026
- Randomised Phase 2b trial of rhIGF-1/rhIGFBP-3 (OHB-607) for bronchopulmonary dysplasia prevention in preterm neonates: study protocol.
Baraldi E, De Luca D, Bonadies L, et al. · BMJ Paediatr Open 2026
- Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.
Salamat-Miller N, Qu W, Chadwick JS, et al. · J Pharm Sci 2022
- The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.
Ren J, Anversa P · Biochem Pharmacol 2015
- Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.
Rinaldi C, Bott LC, Chen KL, et al. · Mol Med 2012
Also in development for Bronchopulmonary Dysplasia
- ZelpultideAT-100, rhSP-DPhase 31 trial
Airway Therapeutics, Inc. · Bronchopulmonary Dysplasia
- Human umbilical cord blood-derived mesenchymal stem cellsSMUP-IA-01, mid-dosePhase 22 trials
Medipost Co Ltd. · Knee Osteoarthritis, Bronchopulmonary Dysplasia, BPD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.